Trial Search Results

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Allergan

Stanford Investigator(s):

Intervention(s):

  • Drug: AGN-199201 ophthalmic solution
  • Drug: AGN-190584 ophthalmic solution
  • Drug: AGN-199201 Vehicle
  • Drug: AGN-190584 Vehicle

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Normal vision at distance, either natural or post corneal laser refractive surgery,
   with presbyopia in each eye and complaints of poor near vision that impacts activities
   of daily living

Exclusion Criteria:

   - Use of any topical ophthalmic medications, including artificial tears other than the
   study medications during the study

   - Corneal abnormalities in either eye that interfere with visual acuity

   - History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery or
   any intraocular surgery

   - Diagnosis of glaucoma or ocular hypertension.

Ages Eligible for Study

40 Years - 55 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting